Financials

Bio-Rad Laboratories Inc. financials

BIO Life Sciences Tools and Services

Bio-Rad Laboratories Inc. is a leading provider of life science research and clinical diagnostic products, founded in 1952 and headquartered in Hercules, California, United States. The company generates revenue through advanced laboratory instruments, reagents, and software sold to research institutions, hospitals, and biopharma companies. Under the leadership of CEO Norman H. Schwartz, Bio-Rad continues to drive innovation with flagship products including the GelDoc and Bio-Plex systems. With strategic investments in digital automation and next-generation diagnostics, the firm is well-positioned for sustained global growth.

Snapshot

Bio-Rad Laboratories Inc. reported $2.58B in revenue in fiscal 2025, up 0.7% year over year, with an operating margin of 1.8%.

Revenue (FY2025): $2.58B
YoY growth: +0.7%
Operating margin: 1.8%
Direction: Expanding

Financial statements

In thousands, USD
	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenues	2,583,200	2,566,500	2,671,200	2,802,200
Cost of Sales	1,243,300	1,187,600	1,244,300	1,234,900
Gross Profit	1,339,900	1,378,900	1,426,900	1,567,300
Selling, General & Administrative Expenses	844,300	814,000	841,700	827,800
Research & Development Expenses	275,600	295,900	247,400	256,900
Other Operating Expenses	172,800	—	—	—
Operating Profit	47,200	269,000	337,800	482,600
Interest Expense	(49,000)	(48,900)	(49,400)	(38,100)
Non-Operating Income	997,300	(2,562,600)	(1,138,500)	(5,148,700)
Total Non-Operating Income	948,300	(2,611,500)	(1,187,900)	(5,186,800)
Income Before Provision for Income Taxes	995,500	(2,342,500)	(850,100)	(4,704,200)
Provision for Income Taxes	235,600	(498,300)	(212,800)	(1,076,700)
Consolidated Net Income	759,900	(1,844,200)	(637,300)	(3,627,500)
Net Income Attributable to Common Shareholders	759,900	(1,844,200)	(637,300)	(3,627,500)
Basic EPS	27.87	-65.36	-21.82	-121.79
Diluted EPS	27.85	-65.36	-21.82	-121.79
Basic Weighted Average Shares Outstanding	27,263	28,214	29,209	29,785
Diluted Weighted Average Shares Outstanding	27,281	28,214	29,209	29,785
Shares Outstanding	26,990	28,011	28,518	29,596

In thousands, USD
	FY 2025	FY 2024	FY 2023	FY 2022
Cash and Cash Equivalents	529,800	488,100	403,800	434,215
Short-Term Investments	1,010,900	1,176,400	1,208,900	1,362,020
Total Cash and Cash Equivalents	1,540,700	1,664,500	1,612,700	1,796,230
Accounts Receivable	460,600	452,500	489,000	494,645
Total Trade Receivables	460,600	452,500	489,000	494,645
Inventories	740,700	760,000	780,500	719,316
Other Current Assets	164,200	153,300	166,100	147,783
Total Current Assets	2,906,200	3,030,300	3,048,300	3,157,980
Net Property, Plant & Equipment	709,900	688,600	723,700	679,564
Net Intangible Assets	174,300	293,600	320,500	332,147
Goodwill	579,800	410,500	413,600	406,488
Long-Term Investments	6,103,600	4,839,200	7,698,100	8,830,890
Other Long-Term Assets	102,700	101,900	94,900	94,599
Total Assets	10,576,500	9,364,100	12,299,100	13,501,700
Accounts Payable	129,000	122,300	144,600	135,041
Accrued Expenses	172,300	124,200	139,900	194,790
Current Portion of Long-Term Debt	1,300	1,200	500	465
Current Portion of Leases	36,100	41,700	40,400	36,336
Other Current Liabilities	178,300	178,400	197,400	202,076
Total Current Liabilities	517,000	467,800	522,800	568,708
Long-Term Debt	1,201,700	1,200,400	1,199,100	1,197,720
Leases	145,700	131,400	165,500	153,597
Other Long-Term Liabilities	1,258,500	995,200	1,670,500	1,966,390
Total Long-Term Liabilities	2,605,900	2,327,000	3,035,100	3,317,710
Total Liabilities	3,122,900	2,794,800	3,557,900	3,886,410
Common Stock	—	—	—	3
Treasury Stock	(1,009,600)	(772,100)	(632,500)	(263,586)
Additional Paid-in Capital	476,000	463,200	449,100	447,454
Accumulated Other Comprehensive Income	(189,100)	(538,200)	(336,000)	(466,822)
Retained Earnings	8,176,300	7,416,400	9,260,600	9,898,200
Total Common Shareholders' Equity	7,453,600	6,569,300	8,741,200	9,615,250
Total Shareholders' Equity	7,453,600	6,569,300	8,741,200	9,615,250
Total Liabilities and Shareholders' Equity	10,576,500	9,364,100	12,299,100	13,501,700

In thousands, USD
	FY 2025	FY 2024	FY 2023	FY 2022
Net Income	759,900	(1,844,200)	(637,300)	—
Depreciation & Amortization	165,400	151,600	145,900	—
Share-Based Compensation Expense	58,000	62,300	61,300	—
Other Adjustments	(508,800)	2,122,300	956,200	—
Changes in Trade Receivables	19,600	16,200	11,400	—
Changes in Inventories	68,900	8,500	(46,300)	—
Changes in Accounts Payable	(100)	(40,900)	(51,800)	—
Changes in Income Taxes Payable	1,500	24,100	(21,300)	—
Changes in Other Operating Activities	(32,200)	(44,700)	(43,200)	—
Cash from Operating Activities	532,200	455,200	374,900	194,400
Capital Expenditure	(157,600)	(165,600)	(156,700)	(112,800)
Proceeds from Sale of Property, Plant & Equipment	100	100	200	200
Purchases of Intangible Assets	—	—	—	(1,500)
Purchases of Investments	(669,300)	(1,276,600)	(689,000)	(2,060,200)
Proceeds from Sale of Investments	855,600	1,305,300	863,200	1,066,000
Payments for Business Acquisitions	(218,500)	(23,400)	—	(100,700)
Proceeds from Business Divestments	—	—	2,500	1,400
Cash from Investing Activities	(189,700)	(160,200)	20,200	(1,207,600)
Issuance of Long-Term Debt	—	—	—	1,186,200
Repayments of Long-Term Debt	(500)	(400)	(500)	(500)
Net Issuance / (Repayments) of Long-Term Debt	(500)	(400)	(500)	1,185,700
Issuance of Common Shares	15,800	19,200	18,500	17,600
Repurchases of Common Shares	(295,500)	(203,600)	(428,700)	(215,700)
Net Issuance / (Repurchases) of Common Shares	(279,700)	(184,400)	(410,200)	(198,100)
Other Financing Activities	(3,000)	(34,000)	(14,900)	(14,000)
Cash from Financing Activities	(283,200)	(218,800)	(425,600)	973,600
Effect of Exchange Rate Changes on Cash and Cash Equivalents	(16,900)	9,200	400	3,000
Increase / (Decrease) in Cash, Cash Equivalents and Restricted Cash	42,400	85,400	(30,100)	(36,600)

Key metrics

$8.18B

Market Cap

10.88x

P/E

3.17x

P/S

37.73x

EV/EBITDA

10.8%

Return on Equity

0.4%

Return on Invested Capital

5.62x

Current Ratio

14.5%

Free Cash Flow Margin

Quarterly trend

Quarter	Revenue	YoY growth	Operating margin	Operating income
Q1 2026	$592M	+1.1%	5.8%	$34M
Q4 2025	$693M	+3.9%	7.8%	$54M
Q3 2025	$653M	+0.5%	10.0%	$65M
Q2 2025	$652M	+2.1%	11.8%	$77M
Q1 2025	$585M	—	4.0%	$24M
Q4 2024	$668M	—	8.7%	$58M
Q3 2024	$650M	—	9.9%	$64M
Q2 2024	$638M	—	15.9%	$102M

Margins

51.9%

Gross margin

1.8%

Operating margin

29.4%

Net margin

SourceCompany financial filings (income statement, balance sheet, cash flow) Last updated2026-06-19

Snapshot

Financial statements

Key metrics

Quarterly trend

Margins

More on Bio-Rad Laboratories Inc.

See how VectorShift works for your firm